Amgen inc AMGN.US 總覽分析
)AMGN 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，股利評分名列前茅，值得長期累積部位。若想獲得較好的進場時機，可參考技術面趨勢與波段評分
AMGN 近期報酬表現
-1.37%
Amgen inc
1.31%
同產業平均
0.58%
S&P500
與 AMGN 同產業的標的表現
- ABBV Abbvie inc價值 5 分趨勢 3 分波段 4 分籌碼 4 分股利 5 分查看更多
AMGN 公司資訊
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people's lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.